Novartis

Big Pharma's Intellectual Property Blues

Big Pharma's Intellectual Property Blues

Motley Fool

With $135M rights deal, Questcor locks up rival to its pricey Acthar drug

With $135M rights deal, Questcor locks up rival to its pricey Acthar drug

Fierce Pharma

Questcor Pays $135 Million to Acquire Rights to a Competitor’s Drug

Questcor Pays $135 Million to Acquire Rights to a Competitor’s Drug

NY Times

These 2 Health Care Stocks Could Win Big With FDA's New 'Breakthrough' Status

These 2 Health Care Stocks Could Win Big With FDA's New 'Breakthrough' Status

Yahoo/Street Authority

Novartis, Sun Pharma Gleevec patent battle moves to U.S.

Novartis, Sun Pharma Gleevec patent battle moves to U.S.

Fierce Pharma

Novartis: 5-Year Revenue Outlook

Novartis: 5-Year Revenue Outlook

Seeking Alpha

Questcor Surges on Drug Acquisition

Questcor Surges on Drug Acquisition

Yahoo/Zacks

Juicy Dividends From the Three Pharmaceutical Giants

Juicy Dividends From the Three Pharmaceutical Giants

Motley Fool

When It Comes To Biotech, Diversity Is Key

When It Comes To Biotech, Diversity Is Key

Seeking Alpha

AstraZeneca - Conducting Major Acquisitions

AstraZeneca - Conducting Major Acquisitions

Seeking Alpha